The management of fibromyalgia syndrome (FMS) has traditionally been multimodal and multidisciplinary, and has included the use of education, physical modalities, and medication. In this article, an acronym is offered to help the clinician remember the important components of management. An improved understanding of the pathogenesis of this condition has allowed substantial refinements in its treatment. This is particularly true for medications that target specific symptom domains, allowing individualization of therapy. This article reviews medications that treat pain and other FMS side effects with monotherapy. In addition, a logical basis is provided to help the clinician design strategic polypharmacy.
|Idioma original||English (US)|
|Número de páginas||9|
|Estado||Published - sept 2006|
ASJC Scopus subject areas
- Psychiatry and Mental health